- |||||||||| Vistide (cidofovir) / Gilead
[VIRTUAL] Hemorrhagic Cystitis : 8 Year Experience from a North Indian Tertiary Care Teaching Hospital () - Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3062;
Pharmacological management included- reduction in immunosuppression where possible, antibiotics as per urine culture sensitivity (n=3), Cidofovir (n=2), Ribavirin(n=2), Levofloxacin (n=6), Leflunomide(n=1). Incidence of HC in study was 11.3% and was more common in non-MSD, ABO incompatible HSCT ,in patients with grade 3-4 aGVHD , suggesting the role of stringent monitoring for HC in patients with these risk factors for early detection and treatment for better outcome
- |||||||||| Vistide (cidofovir) / Gilead
[VIRTUAL] Hemorrhagic Cystitis : 8 Year Experience from a North Indian Tertiary Care Teaching Hospital () - Jan 27, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_3061;
Pharmacological management included- reduction in immunosuppression where possible, antibiotics as per urine culture sensitivity (n=3), Cidofovir (n=2), Ribavirin(n=2), Levofloxacin (n=6), Leflunomide(n=1). Incidence of HC in study was 11.3% and was more common in non-MSD, ABO incompatible HSCT ,in patients with grade 3-4 aGVHD , suggesting the role of stringent monitoring for HC in patients with these risk factors for early detection and treatment for better outcome
- |||||||||| cyclosporine / Generic mfg.
Clinical, Journal: Effects of oral administration of 5 immunosuppressive agents on activated T-cell cytokine expression in healthy dogs. (Pubmed Central) - Jan 26, 2021
Incidence of HC in study was 11.3% and was more common in non-MSD, ABO incompatible HSCT ,in patients with grade 3-4 aGVHD , suggesting the role of stringent monitoring for HC in patients with these risk factors for early detection and treatment for better outcome Prednisone and cyclosporine both affected expression of IL-2 and IFN-γ, suggesting that both have the ability to influence results when utilizing pharmacodynamic monitoring of cyclosporine treatment.
- |||||||||| methotrexate / Generic mfg.
Journal: Management issues in rheumatoid arthritis-associated interstitial lung disease. (Pubmed Central) - Jan 26, 2021
With little high-quality evidence to guide the management of RA-ILD, multidisciplinary teams with expertise in RA-ILD are highly valuable for diagnosing and treating RA-ILD. Clinical and translational research in RA-ILD is needed to fill the many evidence gaps.
- |||||||||| methotrexate / Generic mfg.
Journal: Antirheumatic medications in pregnancy and breastfeeding. (Pubmed Central) - Jan 26, 2021
Clinical and translational research in RA-ILD is needed to fill the many evidence gaps. Because many patients are hesitant to use antirheumatic medications during pregnancy, honest and accurate discussions about pregnancy planning and management are important to help women make decisions that are in their and their offspring's best interest.
- |||||||||| leflunomide / Generic mfg.
Clinical, Journal: A recalcitrant case of ulcerative lichen planus responsive to leflunomide. (Pubmed Central) - Jan 23, 2021
1(a)) Previous treatments included dapsone, oral and topical steroids, methotrexate, isotretinoin, cyclosporine, antibiotics causing modest improvement only. The patient was receiving methotrexate 12.5mg/week for a month when she presented to us and it was continued along with topical 0.05% clobetasol propionate ointment, but there was no improvement even after 2 months of additional treatment.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University
Journal: Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies. (Pubmed Central) - Jan 23, 2021
We provide a detailed discussion of efficacy and safety for the most commonly used medications-including methotrexate, cyclosporine, and acitretin-and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch upon a number of other medications, including fumaric acid esters (used outside the US) and therapies that are no longer widely used for the treatment of psoriasis, i.e. hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus.
- |||||||||| Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
Biomarker, Review, Journal: Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. (Pubmed Central) - Jan 23, 2021
Abatacept is more effective in patients with high CRP, high disease activity and polyarticular involvement. Finally, there are no available data with the anti IL17 These factors are some arguments to help clinicians, but comparative study are needed to conclude.
- |||||||||| methotrexate / Generic mfg.
Review, Journal: Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. (Pubmed Central) - Jan 20, 2021
Leflunomide and sulfasalazine are sound alternatives, whereas (hydroxy)chloroquine is primarily used in combination with other csDMARDs...Combining different csDMARDs is especially attractive in lower income settings given the evidence proving (almost) equal efficacy and safety of the csDMARD combination approach compared to the combination of targeted agents with a csDMARD. The aim of this review is to provide a clinically oriented insight into the pharmacology of each csDMARD and their place in treatment algorithms.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Journal: Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept. (Pubmed Central) - Jan 8, 2021
After confirmation of both diagnoses, we initiated a tumor necrosis factor (TNF)-α-directed therapy with the fusion protein etanercept resulting in significant improvement of both conditions. This case report aims to highlight the rare colocalization of psoriasis and lichen planus, the rare entity of annular atrophic lichen planus, and to discuss a possible beneficial impact of certain TNF-α inhibitors on subtypes of lichen planus.
- |||||||||| leflunomide / Generic mfg.
Clinical, Journal: The outcomes of bariatric surgery on rheumatoid arthritis disease activity: a prospective cohort study. (Pubmed Central) - Jan 1, 2021
Compared to baseline, after 12 months, a significant reduction was observed in the use of leflunomide, biological agents, combination treatments, and NSAIDs in both groups (p < 0.05 or p < 0.01)...Compared to non-surgical patients, in RA patients with obesity, weight loss after bariatric surgery was associated with lower disease activity. Medication tapering for RA in patients who underwent bariatric surgery was not superior to that in non-surgical patients.
- |||||||||| brequinar (DUP 785) / BMS, Clear Creek Bio
Journal: The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. (Pubmed Central) - Dec 22, 2020
Our previously described brequinar analogue 41 was also synergistic with dipyridamole as were the FDA-approved DHODH inhibitors leflunomide and teriflunomide but the latter required much higher concentrations than brequinar. Therefore, a combination of brequinar and ENT inhibitors presents a potential anti-cancer strategy in select tumors.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University
Journal: Cardiovascular risk of synthetic, non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). (Pubmed Central) - Dec 18, 2020
Design of future studies should include areas with lack of evidence, such as the risk for heart failure, arrhythmias and valvular heart disease. The clinically relevant question whether synthetic, non-biologic DMARDs are inferior to biologic DMARDs in terms of CVD outcomes still remains not adequately addressed.
- |||||||||| methotrexate / Generic mfg., leflunomide / Generic mfg.
Clinical, Journal, Combination therapy, Monotherapy: Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). (Pubmed Central) - Dec 18, 2020
This is, to our knowledge, the first randomized, placebo-controlled, double-blind clinical trial assessing the effectiveness of MTX and LEF combination therapy in patients with PsA. The study will provide important information for treatment strategies and treatment recommendations.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases. (Pubmed Central) - Dec 17, 2020
The pharmacokinetics of biological agents such as rituximab or belimumab are not affected by ESRD, and dose adjustments are not necessary. Collaboration between rheumatologists and nephrologists is needed more than ever and is expected to produce a complementary effect and achieve better outcomes in clinical settings, although this cooperation has not always been conducted appropriately.
- |||||||||| leflunomide / Generic mfg.
Trial initiation date: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov) - Dec 17, 2020
P1, N=10, Recruiting,
Collaboration between rheumatologists and nephrologists is needed more than ever and is expected to produce a complementary effect and achieve better outcomes in clinical settings, although this cooperation has not always been conducted appropriately. Initiation date: Jun 2020 --> Oct 2020
- |||||||||| methotrexate / Generic mfg., leflunomide / Generic mfg.
Clinical, Journal: Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. (Pubmed Central) - Dec 10, 2020
Patients with high baseline C-reactive protein levels (⩾15 mg/L) carried a higher risk of treatment resistance (OR = 1.36, 95% CI 1.07-13.41, p = 0.06) and disease relapse (HR = 2.51, 95% CI 1.36-12.98, p = 0.04). LEF might provide a quicker treatment response with lower prevalence of disease relapse compared with that elicited in MTX during 12 months follow-up for TAK.
- |||||||||| methotrexate / Generic mfg.
Journal: HHV-6: an unusual cause of cerebellar ataxia. (Pubmed Central) - Nov 26, 2020
Treatment consisted of a 3-week course of intravenous ganciclovir along with physiotherapy. At a 3-month follow-up, repeat MRI brain showed a decrease in size and oedema of the lesion and the patient's neurological function was improved.
- |||||||||| losartan potassium / Generic mfg., leflunomide / Generic mfg.
Clinical, Journal: An overlap of Alport syndrome and rheumatoid arthritis in a patient and literature review. (Pubmed Central) - Nov 25, 2020
we reported an adult man with the coexistence of rheumatoid arthritis and Alport syndrome with the missense mutation in COL4A5 (c.1351 T > C, p.Cys451Arg). Whether the overlap of them is occasional or has a common pathophysiological mechanism is still unclear.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. (Pubmed Central) - Nov 21, 2020
We also identified female gender, increased ESR, and leflunomide use as relevant risk factors for AAA production at BL, whereas methotrexate was protective. Early systematic monitoring of AAA at 3M may, therefore, guide drug switching in these patients.Key Points• Anti-adalimumab antibodies (AAA) production kinetics demonstrated a timely significant increase starting at 3M in juvenile idiopathic arthritis (JIA) patients under adalimumab therapy• Female gender, increased ESR, and leflunomide use were identified as relevant risk factors for AAA production in JIA, whereas methotrexate was protective.
- |||||||||| leflunomide / Generic mfg.
Clinical, Review, Journal: A critical review of the reproductive safety of Leflunomide. (Pubmed Central) - Nov 21, 2020
These studies collectively showed no significant difference in the rates of malformations between exposed and unexposed pregnancies. At present, accumulating human data do not point toward leflunomide as a potent human teratogen, which may inform risk assessment of unintended gestational exposure to leflunomide.
- |||||||||| Benlysta (belimumab) / GSK
[VIRTUAL] Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease () - Nov 11, 2020 - Abstract #ACRARHP2020ACR_ARHP_3356;
A majority would hold methotrexate or leflunomide (66%) and glucocorticoids of 20 mg/day or higher (52%) for 2 weeks or less (Figure 3); and would hold non-TNF biologics (76%), anti TNF-biologics (85%), Janus-kinase inhibitors (78%), anti IL-17/23 biologics (82%), belimumab (77%)immunosuppressive drugs such as azathioprine (64%), for 3-8 weeks (Figure 3)... A better understanding of COVID-19 rheumatic disease healthcare issues using a health-system approach can inform improve the care of Veterans with rheumatic disease and their providers.
- |||||||||| [VIRTUAL] Imaging of Rheumatic Diseases Poster () - Nov 11, 2020 - Abstract #ACRARHP2020ACR_ARHP_3212;
Specifically, the severity of US-detected bone erosions was significantly greater when both positive PD and a greater degree of GS joint inflammation were present. This association was not observed when either component was absent.
|
